WEP Clinical Inc. (WEP) is pleased to announce that it has partnered with Sellas Life Sciences Group, Inc. (“Sellas”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for various cancer indications. Together, they will launch an Expanded Access Program (EAP) for galinpepimut-S (GPS). GPS is an immunotherapeutic which targets the Wilms Tumor 1 (WT1), which is present and over-expressed in an array of hematological malignancies and solid tumors.
The EAP will run alongside the current pivotal REGAL Phase 3 clinical trial for AML patients in their second complete remission (CR2) or in second complete remission with incomplete platelet count recovery (CRp2).
Jas Khera, Managing Director of WEP, said:
“We are excited to be working with Sellas and look forward to supporting the company, and the patients that need GPS, with its expanded access efforts. Sellas has already achieved some great milestones with GPS, and this EAP will allow their team to further support their patient community, which is something we are thrilled to be a part of.”
For health care professionals looking for further information or details on the GPS EAP, please contact/see:
- ExpandedAccessRequests@sellaslife.com
- https://www.sellaslifesciences.com/pipeline/sellas-pipeline/default.aspx#section=eap
About WEP
Established in 2008, WEP is a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available. We have offices located in London, United Kingdom; RTP North Carolina, United States; Lisbon, Portugal; and Dublin, Ireland and possess all the necessary licenses allowing us to meet drug access and distribution needs across all regions, worldwide. We are passionate about helping those in need. For more information, please visit www.wepclinical.com.
About Sellas
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China. For more information on SELLAS, please visit www.sellaslifescience.com.
